NPH insulin

Jump to navigation Jump to search

WikiDoc Resources for NPH insulin

Articles

Most recent articles on NPH insulin

Most cited articles on NPH insulin

Review articles on NPH insulin

Articles on NPH insulin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on NPH insulin

Images of NPH insulin

Photos of NPH insulin

Podcasts & MP3s on NPH insulin

Videos on NPH insulin

Evidence Based Medicine

Cochrane Collaboration on NPH insulin

Bandolier on NPH insulin

TRIP on NPH insulin

Clinical Trials

Ongoing Trials on NPH insulin at Clinical Trials.gov

Trial results on NPH insulin

Clinical Trials on NPH insulin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on NPH insulin

NICE Guidance on NPH insulin

NHS PRODIGY Guidance

FDA on NPH insulin

CDC on NPH insulin

Books

Books on NPH insulin

News

NPH insulin in the news

Be alerted to news on NPH insulin

News trends on NPH insulin

Commentary

Blogs on NPH insulin

Definitions

Definitions of NPH insulin

Patient Resources / Community

Patient resources on NPH insulin

Discussion groups on NPH insulin

Patient Handouts on NPH insulin

Directions to Hospitals Treating NPH insulin

Risk calculators and risk factors for NPH insulin

Healthcare Provider Resources

Symptoms of NPH insulin

Causes & Risk Factors for NPH insulin

Diagnostic studies for NPH insulin

Treatment of NPH insulin

Continuing Medical Education (CME)

CME Programs on NPH insulin

International

NPH insulin en Espanol

NPH insulin en Francais

Business

NPH insulin in the Marketplace

Patents on NPH insulin

Experimental / Informatics

List of terms related to NPH insulin


Neutral Protamine Hagedorn was created in 1946 when Nordisk formulated "isophane" porcine insulin by adding Neutral Protamine Hagedorn or NPH.

This is a suspension of crystalline zinc insulin combined with the positively charged polypeptide, protamine. It has an intermediate duration of action, longer than that of regular insulin, but shorter than ultralente.

History

Hans Christian Hagedorn (1888-1971) and August Krogh (1874-1949) obtained the rights for insulin from Banting and Best in Toronto. In 1923 they formed Nordisk Insulinlaboratorium, and in 1926 with August Kongsted he obtained a Danish Royal Charters as a non-profit foundation.

In 1936 Hagedorn and B. Norman Jensen discovered that the effects of injected insulin could be prolonged by the addition of protamine obtained from the "milt" or semen of river trout. The insulin would be added to the protamine, but the solution would have to be brought to pH 7 for injection. Canada later produced ZPI insulin, a mixture of zinc, protamine and porcine insulin. This mixture only needed to be shaken before injection.

In 1946 Nordisk was able to form crystals of protamine and insulin and marketed it in 1950 as NPH insulin. NPH insulin has the advantage that it can be mixed with an insulin that has a faster onset to complement its longer lasting action.

Eventually all animal insulins were replaced by human recombinant insulin. Human insulin is also complexed with NPH.

Timeline

  • 1926 Nordisk receives Danish charter to produce insulin
  • 1936 Hagedorn discovers that adding protamine to insulin prolongs the effect of insulin
  • 1936 Canadians D.M. Scott and A.M. Fisher formulate zinc insulin mixture and license to Novo
  • 1946 Nordisk crystallizes a protamine and insulin mixture
  • 1950 Nordisk markets NPH insulin
  • 1953 Nordisk markets "Lente" zinc insulin mixtures

See also


Template:WikiDoc Sources